Stifel


Stifel Financial Buys North Atlantic Capital’s Future Venture Investment Business

Stifel Financial has agreed to buy the future business of Maine-based North Atlantic Capital, a venture capital management company. The financial terms of …

Stifel Boosts Price Target for Alibaba Group Holding Ltd (BABA); Here’s Why

Stifel Nicolaus analyst Scott Devitt is out today with a research note on shares of Alibaba Group Holding Ltd (NYSE:BABA), after the eCommerce giant announced revenue growth …

All Eyes On Facebook Inc (FB) 1Q:17 Earnings This Evening

All eyes on Facebook Inc (NASDAQ:FB) as their earnings come out today after the closing bell. In addition to updates on general core advertising trends/performance, …

What’s Next For Gilead Sciences, Inc. (GILD)? An Opportunity In NASH

There are those who are not in Gilead Sciences, Inc.’s (NASDAQ:GILD) corner amid an underwhelming Hepatitis C segment that looks to only continue …

Top Analyst Lifts Price Target for Netflix, Inc. (NFLX) on Back of Positive Outlook

If you’ve somehow avoided all the buzz surrounding Netflix, Inc.s (NASDAQ:NFLX) earnings, Stifel top analyst Scott Devitt is out today with a few insights and a …

Will Q1 Earnings Hold a Surprise for Amazon.com, Inc. (AMZN)? Top Analyst Answers

World’s top online retailer Amazon.com, Inc.

Hedge Funds Are Betting On Apple Inc. (AAPL) This Year

Stifel analyst Aaron Rakers might still be playing it safe on Apple Inc. (NASDAQ:AAPL), but he recognizes a bullish change in the air …

Stifel Bullish on Ambarella Inc (AMBA) Ahead of 2Q:16

We are cautiously optimistic that Ambarella may beat our and consensus revenue estimates, says Stifel

Stifel Analyst Bearish about FreightCar America, Inc. (RAIL)

Stifel analyst Michael Baudendistel downgraded his rating for FreightCar America, Inc. (NASDAQ:RAIL) to a Hold rating after he tempering his Industrial industry outlook.

Stifel Remains Bullish on Clovis Oncology Inc (CLVS) Despite FDA Panel Setback

Shares of Clovis Oncology Inc (NASDAQ:CLVS) tumbled nearly 5% today, after the FDA’s Oncologic Drugs Advisory Committee (ODAC) panel voted 12-1 to wait for Clovis’ randomized …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts